Reports in category Result Update
| AIA Engineering’s Healthy realization and volume growth to sustain. Buy for target price of Rs 3420: Centrum | |
| Company: | AIA Engineering |
| Brokerage: | Centrum |
| Date of report: | May 26, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 18% |
| Summary: | AIAE’s technological leadership in high chrome mill internals, strong growth opportunity in mining sector and superior financial metrics are key business moats |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | AIA Engineering, Centrum |
| Astral Ltd is superior in every respect; outlook strong. Buy for target price of Rs INR 1,983: Nuvama | |
| Company: | Astral Ltd |
| Brokerage: | Nuvama |
| Date of report: | May 18, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 18% |
| Summary: | We remain positive on ASTRA given its: i) market share gains in the core plastic piping business; ii) strong brand recall; iii) product launches (it recently forayed into faucets and sanitaryware, tanks, infrastructure pipes, DWV piping system, valves, and paints to increase its addressable market); iv) strong cash flow and net debt-free Balance Sheet, with an improvement in working capital; and v) robust growth in the adhesives business |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | astral, Nuvama |
| Indian Hotels ARR continues to inch higher. Buy for Target Price of INR410 (+36%): Motilal Oswal | |
| Company: | Indian Hotels |
| Brokerage: | Motilal Oswal |
| Date of report: | February 1, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 36% |
| Summary: | We expect the strong momentum to continue in FY23-25, led by: a) a further improvement in ARR and occupancy due to favorable demand-supply dynamics; b) higher income from management contracts; and c) unlocking value by launching the reimagined and new brands. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Indian Hotels, Motilal Oswal |
| Bajaj Finance Correction offers an attractive entry; upgrade to ADD for Target Price INR 6,700: HDFC Sec | |
| Company: | Bajaj Finance |
| Brokerage: | HDFC Sec |
| Date of report: | January 28, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 16% |
| Summary: | Bajaj Finance (BAF) delivered a strong operating performance, with steady NIMs in a rising interest rate and strong AUM growth (+27% YoY) environment. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Bajaj Finance, HDFC Sec |
| Sell L&T Technology Services (Stock recommended by Saurabh Mukherjea & Hiren Ved) for target price of Rs 3250 (11% downside): DART | |
| Company: | L&T Technology Services, LTTS |
| Brokerage: | Dolat Capital |
| Date of report: | January 12, 2023 |
| Type of Report: | |
| Recommendation: | Sell |
| Upside Potential: | 11% |
| Summary: | Uneasy Shift; Growth & Margin Trajectory Remain a Concern |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Dolat Capital, L&T Technology Services |
| Can Fin Homes is in the pink of health. Growth trajectory is intact. Buy for target price of Rs 630 (29% gain): Motilal Oswal | |
| Company: | Can Fin Homes |
| Brokerage: | Motilal Oswal |
| Date of report: | December 23, 2022 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 29% |
| Summary: | CANF, in our view, is a franchise which has proven its astute underwriting, strong risk management, and inclination to deliver industry-leading loan growth in the mortgage sector at least (if not more) over the last decade |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Can Fin Homes, Motilal Oswal |
| GAIL’s Valuations remain overly pessimistic and ignore the solid business model and strong long-term prospects: ICICI Securities | |
| Company: | GAIL |
| Brokerage: | ICICI Securities |
| Date of report: | December 20, 2022 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 30% |
| Summary: | We value GAIL on the basis of FY24E EV/EBITDA multiples of 4-5.5x applied to various segments, leading to a target price of Rs127/sh (implying 30% upside). Current valuations of 6.3x FY24E EPS and 5.3x FY24E EV/EBITDA remain well below 5-year valuation bands. Even at our target price, P/E of 8.2x FY24E EPS, and |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | GAIL, ICICI Securities |
| Indian Hotels is rapid scaling up margin-accretive new businesses. Buy for target price of Rs 390: Motilal Oswal | |
| Company: | Indian Hotels |
| Brokerage: | Motilal Oswal |
| Date of report: | December 19, 2022 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 19% |
| Summary: | Indian Hotel’s (IH’s) new and re-imagined businesses Ama Stays, Qmin, Chambers, and Management contracts are expected to scale up rapidly on the lower base and high growth runway. These businesses are margin accretive with higher margin flowthrough, thereby driving up the RoCE. The new business is expected to contribute ~26% to the company’s operating profits by FY25. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Indian Hotels, Motilal Oswal |
| JB Chemicals is the preferred pick in the Pharma sector: Nirmal Bang | |
| Company: | JB Chem |
| Brokerage: | Nirmal Bang |
| Date of report: | December 18, 2022 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 15.2% |
| Summary: | JB Chem has 7 formulations facilities and 1 API facility with most of the units approved by all major compliance agencies, including units TI10 (OSD), T20 (OSD) and D9 (API), which are USFDA compliant as well. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | JB Chem, Nirmal Bang |
| Worst is behind Balrampur Chini. Buy for Target Price of Rs 465 (21.6% Upside) | |
| Company: | balrampur chini |
| Brokerage: | jmfics |
| Date of report: | December 15, 2022 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 21.6% |
| Summary: | We remain positive on the sugar sector (especially efficient companies) as government policies (sugarcane price/MSP/ethanol prices) will ensure survival of the weakest. While the regulation of sugar exports appears optically negative, we are convinced that it is aimed at a) ensuring adequate stock for local consumption, thus avoiding any undesired rally in domestic prices, and b) continuity in the ethanol programme (ethanol momentum could get upset in case of a significant rally in sugar prices). BRCM continues to be the best among the sugar pack, in our view. We maintain BUY rating on Balrampur Chini (CMP-INR 374; Sep’23TP- INR 465). |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | balrampur chini, jm, jmfics |